Organization (Academic)
George Mason University
ClinicalTrials.gov lists George Mason University as lead sponsor of 43 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 10 registered with a 2026 start date. The dashed outline is the pace from the 7 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo George Mason University, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers George Mason University: 43 lead-sponsored trials and 1 legal-entity registration.
Disease areas (59)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Substance-Related Disorders | 14 |
| Obesity | 5 |
| Acquired Immunodeficiency Syndrome | 3 |
| Breast Neoplasms | 3 |
| Cognitive Dysfunction | 3 |
Showing 5 of 59 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 10 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 7 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 7 |
| 2018 | 4 |
| 2017 | 4 |
Showing 10 of 22 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 22 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Capsaicin | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=10) | 44% on time (n=9) |
Journals published in (205)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of biomechanics | 12 |
| Osteoarthritis and cartilage | 11 |
| Journal of applied physiology (Bethesda, Md. : 1985) | 8 |
| Arthritis and rheumatism | 6 |
| Journal of orthopaedic research : official publication of the Orthopaedic Research Society | 5 |
Showing 5 of 205 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 82 | 32 | 2025-12-09 |
Financing and grant events (144)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-24 | NIH grant | 674,483 | Reporter |
| 2025-09-24 | NIH grant | 374,759 | Reporter |
| 2025-09-08 | NIH grant | 677,026 | Reporter |
| 2025-09-05 | NIH grant | 37,580 | Reporter |
| 2025-09-03 | NIH grant | 83,477 | Reporter |
Showing 5 of 144 events.
Organization relationships (14)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 3 |
| Georgetown University | Co sponsors trial with | 2 |
| Howard University | Co sponsors trial with | 2 |
| Yale University | Co sponsors trial with | 2 |
| Emory University | Co sponsors trial with | 1 |
Showing 5 of 14 relationships.
Latest dated events (299)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 299 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| GEORGE MASON UNIVERSITY | Certificate of accreditation | Active |
Biomarker capability evidence (52)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial inclusion criteria |
| F3 | Trial collaborator | Named in trial inclusion criteria |
| F3 | Trial collaborator | Named in trial inclusion criteria |
| FBLN5 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 52 evidence rows.
Biomarkers this organization publishes on (395)
Shown in this order: most publications first.
Showing 5 of 395 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.